안명주 (성균관대학교 의과대학)님 | 한빛사연구자 > 한빛사

성균관대학교 의과대학

CV File

종양의학

최종업데이트 2022.06.22.

- 안명주(성균관대학교 의과대학)
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC
- J. Thorac. Oncol., Jun 12 2025, S1556-0864(25)00761-0 | https://doi.org/10.1016/j.jtho.2025.06.002
- 2025-06
- 의약학
- 한빛사논문
- 안명주(성균관대학교 의과대학)
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
- Ann. Oncol., May 22 2025, S0923-7534(25)00157-7 | https://doi.org/10.1016/j.annonc.2025.04.003
- 2025-05
- 한빛사논문
- 안명주(성균관대학교 의과대학)
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
- J. Clin. Oncol., Sep 09 2024, | https://doi.org/10.1200/JCO-24-01544
- 2024-09
- 의약학
- 한빛사논문
Clinical Utility of Tumor-Naïve Pre-surgical ctDNA Detection in Early-stage NSCLC
- J. Thorac. Oncol., Available online 9 July 2024 | https://doi.org/10.1016/j.jtho.2024.07.002
- 2024-07
- 의약학
- 한빛사논문
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
- J. Clin. Oncol., Jun 03 2024, | https://doi.org/10.1200/JCO.24.00708
- 2024-06
- 의약학
- 한빛사논문
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
- J. Thorac. Oncol., Sep 2018, 13 (9) S1556-0864(18)30673-7 | https://doi.org/10.1016/j.jtho.2018.05.026
- 2018-09
- 의약학
- 한빛사논문
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
- J. Clin. Oncol., Oct 20 2023, | https://doi.org/10.1200/JCO.23.01891
- 2023-10
- 의약학
- 한빛사논문
- 안명주(성균관대학교 의과대학)
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
- N. Engl. J. Med., Oct 20 2023, | https://doi.org/10.1056/NEJMoa2307980
- 2023-10
- 의약학
- 한빛사논문
- 안명주(성균관대학교 의과대학)
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
- J. Thorac. Oncol., Available online 11 September 2023 | https://doi.org/10.1016/j.jtho.2023.06.016
- 2023-09
- 의약학
- 한빛사논문
- 안명주(성균관대학교 의과대학)
Durvalumab in Combination with Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
- J. Thorac. Oncol., Available online 29 June 2023 | https://doi.org/10.1016/j.jtho.2023.06.013
- 2023-06
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기